Form 4: Natera Co-Founder Jonathan Sheena Executes Planned Stock Sales

Natera, Inc. Director and Co-Founder Jonathan Sheena sold 3,000 shares of common stock on July 2, 2025, through pre-arranged Rule 10b5-1 trading plans.

Summary

• Jonathan Sheena, a Director and Co-Founder of Natera, Inc. (NTRA), sold a total of 3,000 shares of Natera common stock on July 2, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted by Mr. Sheena on June 7, 2024.
• Sales included 200 shares at a weighted average price of $159.225, 1,092 shares at $160.105, and 208 shares at $161.2274, all indirectly held by Caraluna 1 Trust.
• Additional sales included 300 shares at $159.14, 1,011 shares at $160.1079, and 189 shares at $161.2867, all indirectly held by Caraluna 2 Trust.
• Following these transactions, Mr. Sheena directly owns 248,774 shares of common stock.
• Indirect beneficial ownership through Caraluna 1 Trust is 35,782 shares, and through Caraluna 2 Trust is 35,782 shares, though Mr. Sheena disclaims beneficial ownership over these trust-held securities.

Sentiment

Score: 5

Explanation: The document reports a routine, pre-scheduled insider stock sale under a Rule 10b5-1 plan. This type of transaction is generally considered neutral as it is not typically indicative of management's immediate sentiment about the company's prospects, unlike open market purchases or unscheduled sales.

Future Outlook

This Form 4 filing reports past transactions and does not contain forward-looking statements or guidance regarding Natera, Inc.'s future performance or strategic outlook.

Management Comments

• The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.
• The Reporting Person disclaims beneficial ownership over such securities [held for the benefit of the beneficiaries of the trust].

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide specific insights into broader industry trends or competitive landscape within the biotechnology or genomics sector. Such transactions are common for executives managing personal finances or diversifying portfolios.

Comparison to Industry Standards

• This Form 4 filing details a standard insider stock sale executed under a Rule 10b5-1 plan. Such pre-arranged trading plans are a common and accepted practice among corporate insiders to manage personal liquidity and avoid accusations of trading on material non-public information. There are no specific comparable companies, projects, or results mentioned in this document to assess against industry standards.

Related Party Transactions

• Jonathan Sheena, a Director and Co-Founder, sold shares indirectly held by Caraluna 1 Trust and Caraluna 2 Trust, for which he disclaims beneficial ownership but are related to his family's interests.

Stakeholder Impact

• Shareholders: The sale of 3,000 shares by a co-founder and director, while routine under a 10b5-1 plan, represents a minor reduction in insider holdings. Given the pre-scheduled nature, it is unlikely to significantly impact investor confidence or perception of the company's immediate future.

Key Dates

Keywords

Natera, NTRA, Jonathan Sheena, Insider Trading, Stock Sale, Form 4, Rule 10b5-1, Biotechnology, Genomics